Aqua is a nasal spray indicated for allergic and non-allergic rhinitis (inflammation of the inside of the nose), and for the treatment of nasal polyps (swelling of the nasal lining).
AstraZeneca, an English-Swedish multinational pharmaceutical and biopharmaceutical company, has agreed to sell rights outside the United States for Rhinocort
Aqua nasal spray to Cilag GmbH International, an affiliate of Johnson & Johnson.
Aqua, a nasal steroid spray, was approved for children six years of age and older.
The companies have signed an agreement giving Pfizer a right of first refusal regarding OTC rights for Rhinocort
Aqua, a pump spray containing the glucocorticosteroid budesonide, with a local anti-inflammatory effect, for the treatment of non-infectious rhinitis (such as hay fever and house dust mite allergy).
The most recent switched products include Flonase Sensimist Allergy Relief from GSK Consumer Health Care, and Rhinocort
Allergy Spray from the McNeil Consumer Products division of Johnson & Johnson.
M2 EQUITYBITES-October 10, 2016-AstraZeneca to sell certain rights for Rhinocort
Aqua nasal spray to Cilag International
is set to launch AstraZeneca's Rhinocort
in the next year.
The companies have signed a right of first refusal regarding OTC rights for Rhinocort
Aqua, a pump spray containing the glucocorticosteroid budesonide, with a local anti-inflammatory effect for the treatment of non-infectious rhinitis (such as hay fever and house dust mite allergy).
Murphy, reporting the findings from the study that was funded by AstraZeneca, makers of Rhinocort
Beconase and Rhinocort
are available on prescription.
But prescription nasal sprays, or topical steroids such as Vancenase, Flonase, Rhinocort
or Nasacort, work very well for allergy sufferers without fear of dependency.
The decline during the forecast period can be attributed to the expected patent expiry of Astelin (azelastine hydrochloride), Nasonex (mometasone furoate), Nasacort AQ (triamcinolone acetonide) and Rhinocort
Aqua (budesonide) in the year 2011, 2014, 2016 (US) and 2017 respectively.